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In the kidney, dystroglycan (DG) has been shown to cover the
basolateral and apical membranes of the podocyte. a-DG is
heavily glycosilated, which is important for its binding to
laminin and agrin in the glomerular basement membrane.
Furthermore, a-DG is negatively charged, which maintains
the filtration slit open. Reactive oxygen species (ROS) are
known to degrade and depolymerize carbohydrates, and to
play a role in several glomerular diseases. Therefore, we
evaluated the effect of ROS on the glycosilation of glomerular
a-DG. By using specific antibodies directed against the core
protein or glyco-epitopes of a-DG, this was studied in a
solid-phase assay, in situ on kidney sections, and in vivo in
adriamycin nephropathy. A ligand overlay assay was used to
study binding of a-DG to its ligands. Exposure to ROS leads to
a loss of carbohydrate epitopes on a-DG both in vitro and on
kidney sections. In the in vitro assays, a decreased binding of
deglycosilated a-DG to laminin and agrin was found. In
adriamycin nephropathy, where radicals play a role, we
observed a loss of a-DG carbohydrate epitopes. We conclude
that deglycosilation of glomerular a-DG by ROS leads to
disruption of the agrin–DG complex, which in vivo may lead
to the detachment of podocytes. Furthermore, loss of
negative charge in the filtration slit may lead to foot process
effacement of podocytes.
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Podocytes are highly specialized visceral epithelial cells,
which cover the outside of the glomerular basement mem-
brane (GBM). Together with the GBM and the fenestrated
glomerular endothelial cells they form the capillary filter,
which allows size- and charge-specific filtration of molecules
from the circulation to the urinary space. Dystroglycan (DG)
is, besides the a3b1-integrin, a major connecting molecule
between the podocyte and the GBM.1 Furthermore, it has
been shown that a-DG covers the apical cell membrane of the
podocyte, where it plays a role in the maintenance of the
filtration slit by its negative charge.1,2 DG has originally been
described as a component of the dystrophin–glycoprotein
complex in skeletal muscle.3 DG, encoded by a single gene,
DAG1, is cleaved into two proteins by post-translational
processing events: the extracellular a-DG and the transmem-
brane b-DG.4 Within the podocyte b-DG is intracellularly
linked to utrophin, which interacts with the actin cyto-
skeleton.1 The extracellular domain of b-DG binds to a-DG,
which on its part interacts with laminin G modules present in
laminin, agrin, and perlecan in the GBM. DG has been shown
to play an important role in basement membrane assembly.
Mice with a targeted disruption of DG (DAG1/) do not
develop Reichert’s membrane, at which stage further deve-
lopment of the embryo stops.5 Blocking of the binding site of
a-DG to laminin with antibody IIH6 in kidney organ culture
pertubates development of epithelium.6 a-DG is heavily
glycosilated, especially by O-mannosyl glycosilation, which is
one of its unique features.7 The predicted molecular weight
of the core protein of a-DG is about 74 kDa, whereas its
apparent molecular mass, as detected by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), is
about 156 kDa in skeletal muscle, ranging from 120 kDa
in brain to 190 kDa in the Torpedo electric organ.8–10 As no
differences in primary protein structure are described, these
observed differences in molecular mass point to different
degrees of glycosilation.11 The glycosilation of a-DG is
necessary for the binding to laminin G. In inherited disorders
of the glycosilation of a-DG, like muscle–eye–brain disease
and Fukuyama-muscular dystrophy, a hypoglycosilated
muscle a-DG is expressed, which shows a decreased binding
to agrin and laminin.12–14
Reactive oxygen species (ROS) are involved in several
forms of experimental nephropathies.15–19 Besides infiltrating
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neutrophils and macrophages, podocytes and other glomer-
ular cells are able to produce ROS.20–23 Agrin is the major
heparan sulfate proteoglycan in the GBM.24,25 Agrin is com-
posed of a core protein with four attached negatively charged
heparan sulfate polysaccharide side chains. We have pre-
viously described that hydroxyl radicals degrade and depoly-
merize these heparan sulfate side chains, whereas the core
protein of agrin remains intact. In the adriamycin nephro-
pathy in the rat, treatment of rats with a scavenger for
hydroxyl radicals protected for heparan sulfate loss from the
GBM and led to a decrease of albuminuria.15
In the present study, we investigate how the glycosilation
of glomerular a-DG is affected by exposure to ROS, and
whether this influences the binding of a-DG to laminin and
agrin. This could reveal a novel mechanism of podocyte loss,
which is associated with progressive decline of kidney func-
tion, proteinuria, and a poor prognosis in several glomerular
diseases.26–28
RESULTS
Differences in accessibility of core protein epitopes of a-DG in
muscle and kidney
As the antibodies against the a-DG core protein as described
by Holt et al.29 are the only ones to stain glomerular a-DG
(data not shown), we raised antibodies against the same three
peptides by the same procedure.12,29–31 All three antibodies
(i.e. affinity purified on the appropriate peptide) showed a
high reactivity with their respective peptide in enzyme-linked
immunosorbent assay (ELISA) (not shown). The speci-
ficity of the anti-a-DG amino acids (a.a.) 549–572 antibody
(sheep anti-rabbit a-DG (ShaRbDG) 549–572), directed at
the binding site for b-DG, was proven in Western blot
analysis and immunoprecipitation (Figure 1, lanes 2 and 5).
While the antibody specific for a-DG a.a. 517–526 (ShaRbDG
517–526) did not reveal a signal in Western blot analysis, it
turned out specific for a-DG in immunoprecipitation
(Figure 1, lane 1). Furthermore, these two antigen-purified
polyclonal a-DG antibodies were used to stain rabbit muscle
and kidney sections (Figure 2). The 517–526 epitope is
only expressed in muscle and weakly in tubuli but not in
glomeruli, whereas the 549–572 epitope is expressed in the
glomerulus as well. To evaluate more precisely the localiza-
tion of the epitope of ShaRbDG 549–572 in the glomerulus,
we performed confocal laser microscopy analysis of double
stainings of ShaRbDG 549–572 with antibodies specific for
agrin (as a marker for the GBM), the carbohydrate epitopes
of a-DG and podocalyxin-like protein (PCLP-1) as markers
for podocytes, and perlecan as a marker for the mesangium.
This suggested an intracellular localization in the podocyte of
the epitope of ShaRbDG 549–572 (Figure 3).
Effect of ROS on glomerular a-DG
To study the effect of ROS on native a-DG, rabbit kidney
sections were exposed to ROS generated via the Haber–Weiss
reaction (Table 1). Different concentrations of ROS were
produced by varying the concentration of xanthine oxidase
(XO). A concentration-dependent loss of the carbohydrate
epitopes of a-DG was observed for IIH6 and VIA4.1, in
which the epitope of IIH6 was more sensitive to ROS
(Figure 4, first and third rows). However, the core epitope of
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Figure 1 | Western blot analysis and immunoprecipitation from
homogenized rabbit muscle by the polyclonal antibodies
ShaRbDG 517–526 and 549–572 directed against the core protein
of a-DG. Antigen affinity-purified sheep polyclonal antibodies against
rabbit a-DG a.a. 517–526 (lane 1) and a.a. 549–572 (lane 2) bound to
gammabind sepharose were able to precipitate rabbit muscular
a-DG. Nonimmune sheep IgG served as a control (lane 3). The input
extract is depicted in lane 4. These (precipitated) extracts were
reduced and subsequently separated by 8% SDS-PAGE and blotted to
nitrocellulose. The blot (lane 1–4) was probed with monoclonal
antibody IIH6. Western blot analysis of unprecipitated rabbit muscle
lysate with ShaRbDG 549–572 revealed a band at approximately
156 kDa (lane 5), which was not observed with nonimmune IgG (lane 6).
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Figure 2 | Indirect immunofluorescence staining of rabbit muscle
and kidney by the polyclonal antibodies ShaRbDG 517–526 and
549–572 against the core protein of a-DG. Antigen affinity-purified
sheep polyclonal antibodies against rabbit a-DG a.a. 517–526 (upper
panels) and a.a. 549–572 (lower panels) stain rabbit skeletal muscle
and kidney sections differently. With ShaRbDG 517–526, a strong
staining of muscle and a weak staining of some tubuli in the kidney
were observed. However, a glomerular staining of a-DG with this
antibody was not detected. With ShaRbDG 549–572 a similar staining
of muscle and tubuli was observed, but strikingly also a glomerular
staining of a-DG was seen (Bar¼ 100mm, asterisk¼glomerulus).
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a-DG was conserved, as revealed by double staining with
ShaRbDG 549–572 (Figure 4, second and fourth rows). This
suggests a differential sensitivity of the respective carbohy-
drate epitopes of the monoclonal anti-a-DG antibodies
IIH6 and VIA4.1 for ROS, whereas the peptide epitope of
ShaRbDG 549–572 was not affected by these concentrations
of ROS. Three scavengers for ROS: superoxide dismutase
(SOD) for superoxide, deferoxamine (DFO) for ferrous
ions, and dimethylthiourea (DMTU) for hydroxyl radicals,
prevented to a certain extent the loss of the carbohydrate
epitopes (Figure 4, columns 4–6).
The effect of ROS on the molecular mass of bovine glome-
rular a-DG was analyzed by SDS-PAGE and Western blot.
With increasing concentrations of XO the epitope of IIH6
disappeared (Figure 5, upper panel), and a band appeared at
approximately 100 kDa, as revealed by ShaRbDG 549–572
(Figure 5, lower panel).
The effect of exposure of a-DG to ROS was quantified
by incubating immobilized bovine glomerular a-DG with
increasing concentrations of XO (Figure 6). Similar to the
observations on kidney sections, the carbohydrate epitope of
monoclonal antibody (MoAb) IIH6 was more sensitive to
ROS than the carbohydrate epitope of MoAb VIA4.1 (Figure
6a and c). Importantly, the core protein was not affected
by ROS, as evaluated by staining with ShaRbDG 549–572
(Figure 6e). As was observed on kidney sections, the loss of
IIH6 and VIA4.1 epitopes could be prevented by either
scavenging hydroxyl radicals or by preventing the formation
of hydroxyl radicals by scavenging the ferrous ions (Figure 6b
and d).
The effect of ROS treatment on the binding of glomerular
a-DG to laminin and agrin was investigated first in a ligand
overlay assay (Figure 7). Agrin and laminin could bind to
a-DG not exposed to ROS, but the binding was lost after
exposure to ROS.
In addition, a solid-phase assay was performed (Figure 8).
At increasing concentrations of XO, a decrease in binding of
Engelbreth–Holm–Swarm (EHS) laminin and bovine glome-
rular agrin to a-DG was observed (Figure 8a and c). Even at
high concentrations of ROS, the a-DG core protein remained
attached to these immunoplates, as measured by ShaRbDG
549–572 (Figure 8e). Scavenging hydroxyl radicals with
DMTU and preventing the formation of hydroxyl radicals
with DFO prevented the loss of binding of both laminin
and agrin to a-DG (Figure 8b and d). In contrast to
the binding studies with MoAb IIH6 and VIA4.1 in
ELISA, SOD treatment protected the binding site of a-DG
for both laminin and agrin. This latter finding implies that
other carbohydrate epitopes, which are not recognized by
IIH6 and VIA4.1, are involved in binding to laminin and
agrin.
Adriamycin nephropathy
The observed deglycosilation of a-DG, both in vitro
accompanied with a decrease in binding of a-DG to agrin
and laminin, questioned the effect of ROS on a-DG in vivo.
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Figure 3 | The epitope of ShaRbDG 549–572 is expressed by
podocytes. Confocal microscopy analysis of double stainings with
ShaRbDG 549–572 (red), and (a) anti-perlecan, (b) anti-agrin, (c) anti-
podocalyxin-like protein, or antibodies against the carbohydrate
epitopes of a-DG ((d) VIA4.1 and (e) IIH6, all green). (a) No
colocalization with the mesangium was observed. (b) All staining
with ShaRbDG 549–572 was found outside the GBM. (c) The cells that
were positive for the podocyte membrane marker PCLP-1 were also
positive for ShaRbDG 549–572. The epitope of the core protein of
a-DG was also localized intracellularly in the podocytes, since in the
merge there is also red staining visible. (d, e) This intracellular
localization is visualized by the double staining with the
carbohydrate epitopes of a-DG, which are expressed on the
podocyte membrane.
Table 1 | Generation of reactive oxygen species
Reaction Scavenger
Haber–Weiss
reaction
Xanthine oxidase
Hypoxanthine-xanthine+uric
acid+O2

Superoxide
dismutase (SOD)
2 O2
+2H+-H2O2+O2
Fenton reaction Fe3++O2
-Fe2++O2 Deferoxamine (DFO)
Fe2++H2O2- KOH+OH
+Fe3+ Dimethylthiourea
(DMTU)
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We observed a decrease in the expression of the specific a-DG
carbohydrate epitopes recognized by IIH6 and VIA4.1 in the
adriamycin-treated rats, which could not be prevented by
scavenging hydroxyl radicals with DMTU (Figure 9). This
seems to be in contrast with our earlier observations that
DMTU prevented partially the depolymerization of heparan
sulfate in adriamycin-injected rats. The expression of other
components of the glomerular DG complex remained stable,
as revealed by the glomerular staining for utrophin. However,
ShaRbDG 549–572 failed to stain (ROS-treated) rat kidney
sections.
The failure to demonstrate the in vivo protection of loss
of a-DG carbohydrate epitope by DMTU in the adriamycin-
treated rat made us compare the in situ susceptibility to
ROS of rat glomerular heparan sulfate on agrin (assessed by
JM403) and the oligosaccharides on a-DG (Figure 10). The
staining of both IIH6 and VIA4.1 was lost at 200 mU XO,
whereas still some staining of JM403 was visible. Further-
more, heparan sulfate loss could be prevented with lower con-
centrations of DMTU compared to loss of oligosaccharides
on a-DG (Figure 10, columns 4 and 5). This indicates that
oligosaccharides on a-DG are more susceptible to ROS than
heparan sulfate. Therefore, prevention of ROS-mediated
deglycosilation of a-DG requires higher concentrations of
DMTU, which was not achieved in vivo in adriamycin
nephropathy.
DISCUSSION
We have raised in sheep new antibodies specific for pep-
tides a.a. 517–526 and 549–572 of a-DG, as described by
others.29,32 Their specificity was proven in ELISA, immuno-
precipitation, Western blot analysis, and immunofluores-
cence. In immunofluorescence, we found an (intracellular)
expression of the epitope of ShaRbDG 549–572 in podocytes.
This localization was recently also found by Pavoni et al.,32
with new antibodies raised against the a.a. 549–569 peptide of
a-DG. It may reflect DG trafficking from the endoplasmatic
reticulum to the Golgi, where it undergoes post-translational
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Figure 4 | Effect of in situ exposure of kidney sections to ROS on carbohydrate epitopes of a-DG. Indirect immunofluorescence of 2 mm
rabbit kidney cryostat sections exposed to ROS. The epitope of antibody IIH6 was lost at the lowest concentration of XO (50 mU/ml), whereas
both epitopes of MoAb IIH6 and VIA4.1 were lost at the highest concentration of XO (200 mU/ml). In all cases, the core epitope of a-DG
remained intact. This ROS-dependent epitope loss at 200 mU/ml of XO was prevented by scavenging the superoxide with SOD (fourth column),
as well as by scavenging hydroxyl radicals with DMTU (sixth column) or preventing the formation of hydroxyl radicals by chelation of ferrous
ions with DFO (fifth column). After scoring of blinded sections, the glomerular staining on a scale from 1–10, the epitope loss compared to
control sections was significantly different (VI4.1 50 mU XO, Po0.05; VIA4.1 200 mU XO, IIH6 50, and 200 mU XO, Po0.01). Furthermore, the
protection by all three scavengers compared to ROS-treated sections was significantly different (Po0.01, Bar¼ 100 mm).
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Figure 5 | Exposure of glomerular a-DG to ROS leads to
hypoglycosilated a-DG. Purified bovine glomerular a-DG was
exposed to increasing concentrations of ROS and subsequently
separated by 4–15% SDS-PAGE. At lower concentrations of XO, the
molecular mass of a-DG decreased, as revealed by probing with IIH6
(upper panel). At higher concentrations of XO the molecular mass
decreased to approximately 100 kDa (arrow), as revealed by probing
with ShaRbDG 549–572 (lower panel).
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processing events. Extracellularly, the epitope is hardly recog-
nized because of sterical hindrance by b-DG, as the epitope
corresponds to the binding site to b-DG. Comparing our two
antibodies to the core protein of a-DG, a difference in the
accessibilities of these epitopes on the core protein of muscle
and glomerular a-DG was found. The epitope of ShaRbDG
549–572 is accessible in muscle, some renal tubuli, and in the
glomerulus, in contrast to ShaRbDG 517–526, which has a
similar accessibility in muscle and renal tubuli, but not in the
glomerulus. As there are no splice variants known for a-DG,
the glomerular epitope of ShaRbDG 517–526 is either masked
by a different tertiary structure in the glomerulus compared
to muscle or, more likely, by a difference in glycosilation. This
may also explain the higher molecular mass of glomerular
a-DG compared to muscle a-DG observed by SDS-PAGE/
Western blot. The peptide 517–526 contains one potential
O-mannosyl glycosilation site at position 520. We suggest
that in glomerular a-DG, in contrast to muscle a-DG, this
site is glycosilated.
ROS play an important role in several forms of
experimental nephropathies. We have previously shown that
ROS can degrade and depolymerize the heparan sulfate side
chains of agrin in vitro as well as in vivo.15 Here, we show that
glomerular a-DG is also sensitive to deglycosilation by ROS,
as determined by the decrease in staining of kidney sections
of two specific carbohydrate epitopes of a-DG recognized by
MoAb IIH6 and VIA4.1, whereas the core epitope was not
affected. Dependent on the concentration of XO, we observed
a decrease in molecular mass of a-DG. First, the high
molecular part of the 150–200 kDa smear disappeared, finally
to a size of approximately 100 kDa. This indicates that some
of the carbohydrate moieties of a-DG are resistant to ROS
treatment, since the predicted molecular mass of completely
unglycosilated a-DG is 74 kDa. The approximate molecular
mass of hypoglycosilated a-DG in muscle–eye–brain disease is
indeed about 74 kDa.12,29 ShaRbDG 549–572 did not stain
the broad smear of the fully glycosilated a-DG from bovine
glomeruli. However, it did stain the more compact smear of
rabbit muscle a-DG at approximately 156 kDa. Apparently,
ShaRbDG 549–572 can only stain bovine glomerular a-DG
in Western blot after exposure to ROS, which may be due
to the more heterogeneous glycosilation of native bovine
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Figure 6 | Exposure of immobilized glomerular a-DG to ROS
leads to loss of carbohydrate epitopes on a-DG. Purified bovine
glomerular a-DG was coated in ELISA plates and exposed to
different concentrations of XO. The carbohydrate epitope of
(a) MoAb IIH6 is more sensitive to ROS than the epitope of (c) MoAb
VIA4.1. At an XO concentration of 50 mU/ml, the concentration
at which in ELISA all staining of a-DG with IIH6 and VIA4.1 was
lost, SOD, DFO or DMTU was added to the reaction buffer. Preventing
the formation of hydroxyl radicals with DFO as well as scavenging
hydroxyl radicals prevented the loss of the epitope of (b) MoAb
IIH6 and (d) VIA4.1. Scavenging the superoxide with SOD only
partially prevented the ROS-mediated epitope loss (b, d). The
binding of IIH6 and VIA4.1 to a-DG not exposed to ROS is set at
100%. (e) Note that the core-protein epitope a.a. 549–572 was
conserved.
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Figure 7 | Ligand overlay assay of purified bovine glomerular
a-DG after exposure to ROS. Purified bovine glomerular a-DG was
either exposed to ROS using an XO concentration of 200 mU/ml
(lanes 5 and 9), or directly separated by 8% SDS-PAGE (lanes 1–4 and
5–8) and blotted to polyvinylidene difluoride membranes. These
membranes were incubated with agrin (lanes 4 and 5) and laminin
(lanes 8 and 9). a-DG was stained by MoAb IIH6 (lane 1), the overlay
lanes were probed for agrin (lanes 3–5, isotype control lane 2) and
laminin (lanes 7–9, isotype control lane 6) using specific antibodies.
Lane 1 shows the presence of a-DG not exposed to ROS as probed by
MoAb IIH6. This purified a-DG did not contain agrin (lane 3). Agrin
could bind to a-DG not exposed to ROS (lane 4), but the binding was
lost after exposure to ROS (lane 5). Purified a-DG still contained a faint
amount of laminin (lane 7). This is probably contamination due to
release of some laminin from the EHS laminin sepharose column used
for purification of a-DG. However, laminin could clearly bind to a-DG
(lane 8), while exposure of a-DG to ROS prevented binding of laminin
(lane 9).
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glomerular a-DG. However, when bovine glomerular a-DG
was immobilized on microtiter plates, the epitope for
ShaRbDG 549–572 could be detected in ELISA, which enabled
us to evaluate the susceptibility of the aDG 549–572 core
epitope to ROS. Also, in ELISA, the carbohydrate epitopes of
a-DG recognized by IIH6 and VIA4.1 are lost upon ROS
treatment. Similar to the experiments on kidney sections, the
epitope of antibody IIH6 is more sensitive to ROS than the
epitope of VIA4.1. Inhibition of the formation of hydroxyl
radicals, as well as scavenging hydroxyl radicals, prevented the
deglycosilation of a-DG. As superoxide and hydrogen
peroxide are still available during scavenging hydroxyl radicals
by DMTU, we conclude that hydroxyl radicals are the main
cause of the observed deglycosilation of a-DG. Scavenging
superoxide by SOD did not completely prevent the loss of
carbohydrate epitopes of a-DG. This might be explained by
the fact that during the degradation of superoxide by SOD
hydrogen peroxide is formed, still allowing some generation
of hydroxyl radicals. We have previously shown that a-DG
also covers the apical membrane of the podocyte, where it
presumably plays a role in the maintenance of the filtration
slit by its negative charge derived from its sialic acid
residues.1,2 Deglycosilation of a-DG by ROS will lead to loss
of this negative charge and may thereby play a role in foot
process effacement. On kidney sections after exposure to ROS,
unpublished experiments from our laboratory indeed show a
loss of staining of Maackia amurensis lectin and Sambuccus
nigra agglutinin (both specific for sialic acid), and many other
lectins.
DG plays a role in the binding of the podocyte to laminin
and agrin in the glomerular basement membrane via its
oligosaccharide side chains. Deglycosilation of a-DG may
lead to a decreased binding to these ligands. Such an effect
has been documented in patients with muscle–eye–brain
disease, Fukuyama muscular dystrophy, or in myd mice,
in which muscle a-DG is hypoglycosilated and the binding of
a-DG to laminin and agrin is severely impaired.12–14 Unfortu-
nately, no information is available about the glycosilation of
glomerular a-DG, kidney function, or proteinuria in these
patients or in this experimental model. In vitro it has been
shown that chemical deglycosilation of muscle a-DG can
disrupt its binding to laminin.8,30,33 Very recently, a loss of
binding has been postulated after ROS exposure of muscle
a-DG to immobilized laminin and agrin.34 However, the
outcome of these experiments could be flawed by the fact
that MoAb VIA4.1 was used to detect binding of a-DG, while
we have shown here that the epitope of VIA4.1 is sensitive
to exposure to ROS. Therefore, we addressed whether
the binding of glomerular a-DG to laminin and agrin is
actually decreased after ROS treatment. In the ligand overlay
assay, we found that laminin and agrin clearly bound to
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Figure 8 | Functional implications of deglycosilation of glomeru-
lar a-DG by ROS. (a) The binding of laminin to purified bovine
glomerular a-DG exposed to ROS decreases in the solid-phase assay.
(b) The decrease in laminin binding to ROS-treated a-DG was
prevented partially by scavenging superoxide with SOD and almost
completely by blocking the formation of hydroxyl radicals with DFO
or scavenging hydroxyl radicals with DMTU (*Po0.01). (c, d) Similar
effects were observed with purified bovine glomerular agrin
(*Po0.01). (e) Importantly, the core protein as measured by ShaRbDG
549–572 was not affected by ROS. The binding of laminin or agrin to
a-DG not exposed to ROS is set at 100%.
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Figure 9 | Expression of carbohydrate epitopes of a-DG in
adriamycin nephropathy. In adriamycin nephropathy (second
column), the expression of the carbohydrate epitopes of a-DG-
specific MoAb IIH6 and VIA4.1 was investigated at day 28, and
revealed a reduced staining with both antibodies (second and third
rows). The expression of utrophin, another component of the DG
complex, was unaltered (first row). In contrast to the in vitro
observations, no protective effect of DMTU was observed on the
expression of these carbohydrate epitopes of a-DG (third column,
Bar¼ 100mm).
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purified native a-DG. This binding was completely lost
upon exposure of a-DG to ROS. In the solid-phase assay,
we observed a substantial decrease, but not a complete
loss, of binding of ROS-treated a-DG to both agrin and
laminin. This partial loss of binding of laminin and agrin to
a-DG in the solid-phase assay was prevented by scavenging
hydroxyl radicals. The discrepancy of the complete loss of
binding in the ligand overlay assay and the partial loss in the
solid phase assay can be explained by either differences
in efficacy of ROS in the fluid or solid phase, or differences
in sensitivity of the solid-phase assay in comparison to
the ligand overlay assay. Nevertheless, both assays show
that deglycosilation of a-DG may have functional conse-
quences for its binding to the ligands agrin and laminin in
the GBM.
A decreased binding of a-DG to laminin and agrin might
therefore lead to detachment of podocytes in vivo. Podocytes
are highly specialized cells, which are unable to replicate.27
A decrease in podocyte number has been correlated
with deterioration and even with progression to end-stage
renal failure in several glomerulopathies.35–38 The number of
podocytes in the urine of patients with systemic lupus
erythematosus and diabetes has been shown to correlate with
disease activity.39–42 Preservation of podocyte anchorage to
the GBM may be a new target in the therapy of these
glomerular diseases.
In adriamycin nephropathy, we showed previously that
scavenging hydroxyl radicals with DMTU can prevent the
depolymerization of heparan sulfate and lowers proteinuria
by 50%. Adriamycin nephropathy is a model for minimal
change nephropathy, a human podocyte disease with little or
no abnormalities in light microscopy. However, in electron
microscopy a fusion of foot processes of podocytes is
revealed, accompanied by a loss of anionic charge selectivity
leading to a high level of albuminuria.43 Previously, a
decrease of the epitope of antibody VIA4.1 has been shown
in patients with minimal change nephropathy.44 In adria-
mycin nephropathy, we observed also a decrease of both
carbohydrate epitopes of IIH6 and VIA4.1 on a-DG, whereas
the expression of another component of the DG complex,
utrophin, remained unaltered. However, the decrease of these
a-DG carbohydrate epitopes in adriamycin nephropathy was
not prevented by treatment with DMTU. We could demon-
strate in situ that carbohydrate epitopes on rat glomerular
a-DG were more susceptible to ROS than the heparan sulfate
side chains on agrin. This difference may explain the failure
of chosen DMTU doses to prevent in vivo deglycosilation
of a-DG, and explain the persistence of a certain degree of
albuminuria.15 Furthermore, it might be due to the fact that
after deglycosilation a-DG is endocytosed by podocytes, as
was recently reported.34 Alternatively, some carbohydrate
epitopes on glomerular a-DG, other than those recognized by
IIH6 and VIA4.1, may be preserved by DMTU. Nevertheless,
our data from adriamycin nephropathy demonstrate that
a-DG on podocytes is rather sensitive to ROS.
In conclusion, we have shown that glomerular a-DG can
be deglycosilated by hydroxyl radicals, which leads to an
impaired binding to laminin and agrin. Furthermore, this
may lead to a loss of negative charge of the filtration slit, and
thereby to foot process effacement. We speculate that the
disruption of the glomerular a-DG–agrin complex may lead
to proteinuria, podocyte loss, and ultimately to a decrease of
renal function.
MATERIALS AND METHODS
Antibodies and immunofluorescence
ShaRbDG core protein antibodies were developed with peptides
corresponding to rabbit a-DG a.a. 500–517, 517–526, and 549–572,
IIH
6
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40
3
No ROS ROS
50 mU XO
ROS
200 mU XO
200 ROS
0.04 M DMTU
200 ROS
0.4 M DMTU
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.1
Figure 10 | Carbohydrate epitopes of a-DG are more susceptible to ROS than heparan sulfate on agrin. Rat kidney sections were exposed
to ROS. The carbohydrate epitopes of a-DG IIH6 and VIA4.1 are completely lost after exposure to 200 mU XO (second and third rows), whereas
the expression of heparan sulfate (JM403) is partially conserved (first row). Furthermore, the epitope of JM403 was protected against ROS at a
lower concentration DMTU (fourth and fifth columns, Bar¼ 100 mm).
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as described previously.29 Antibodies were affinity purified on
coupled peptides (sulfo link coupling gel, Pierce, Rockford, IL).
Specificity was evaluated by peptide ELISA and immunoprecipita-
tion with purified antibodies bound to gammabind sepharose
(Pharmacia, Uppsala, Sweden) using homogenized rabbit muscle
extract in 50 mM Tris[hydroxymethyl]aminomethane (Sigma, Triz-
ma base), 100 mM NaCl, 1% Triton X-100 (Sigma, St Louis, MO),
pH 7.5. SDS-PAGE and Western blot analysis were performed
according to the methods of Laemmli.45 Immunofluorescence was
performed as described previously.2,15 Antibodies and conjugates are
listed in Table 2.
Purification of bovine glomerular a-DG and agrin
Glomeruli were obtained from kidneys of 4-year-old cows by
gradual sieving.46–48 Glomeruli were dissolved in 0.1% collagenase
type II (Invitrogen Corporation, Paisley, UK) in 50 mM Tris, pH 7.6,
incubated for 15 min at 371C, and spun down. The pellet was
resuspended in 50 mM Tris, 1 mM phenylmethylsulfonyl fluoride
(Sigma), and 0.75 mM benzamidine (Sigma), pH 7.6. A pH 11
extraction was performed and subsequently a-DG was affinity puri-
fied on EHS laminin (Campro Scientific, Berlin, Germany) 4 mg
coupled to 20 ml sepharose S4B (Pharmacia).49,50
Agrin was purified from the pellet of the pH 11 extraction by
guanidine HCl extraction.24,48 From this extract, agrin was purified
with affinity chromatography using monoclonal antibody JM170.
Generation of ROS and effects on a-DG
ROS were generated as described previously (Table 1).15,51 Either
kidney sections, dissolved or immobilized purified a-DG, were
incubated with ROS, after which they were thoroughly washed in
phosphate-buffered saline. In vivo, the effect of ROS was studied in
adriamycin nephropathy, performed as described.15 All animal
experiments were approved by the local ethics committee.
Purified a-DG was coated in Maxisorp plates (Nunc, VWR
International, Amsterdam, The Netherlands) and exposed to ROS.
Blocking was performed with 5% non-fat dry milk (Biorad,
Hercules, CA) in phosphate-buffered saline. For the ELISA IIH6
or VIA4.1 was used (Table 2) in non-fat dry milk/phosphate-
buffered saline. For the ligand overlay and solid-phase assays,
polyvinylidene difluoride or Maxisorp-bound a-DG was incubated
with 10 nM EHS laminin or purified agrin in 50 mM Tris, 137 mM
NaCl, 1 mM CaCl2, 1 mM MgCl2, pH 7.6 (laminin binding buffer),
and gently shaken for 16 h at 41C.12 Laminin and agrin were
visualized by using specific antibodies (Table 2). Chemiluminescent
peroxidase substrate (Sigma) or 3,30,5,50-tetramethyl benzidene
(SFRI Diagnostics, Berganton, France) was used as developing
solution.
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